HANSA BIOPHARMA

Conference Call Presentation

Interim Report Q2 2022

Lund, July 19, 2022

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

HANSA BIOPHARMA

Continued solid sales in Q2; Positive recommendation by NICE; Patient enrollment completed in AMR; Peter Nicklin appointed as new Chairman of the Board

Highlights for the second quarter of 2022

✓ Launch activities and market access efforts in EU progressing as planned

- Continued solid sales, with SEK 19.5m in product sales; Total revenue of SEK 26.4m
- Market access obtained in England, Wales and Nothern Ireland as NICE recommends Idefirix® for desensitization of highly sensitized patients
- France grants Idefirix® ASMR 3 rating by the Transparency Commission (TC) of the French National Authority for Health (HAS)
- Market access has now been secured in 7 countries and procedures are ongoing in 11 countries, including Spain and Italy
- Temporary marketing authorization granted for Idefirix® in Switzerland

✓ Clinical pipeline

- U.S. ConfIdeS Study in kidney transplantation: 22/64 patients enrolled
- Anti-GBM: Expect to commence Phase 3 study later this year, as previously guided
- AMR: Patient enrollment completed; First data read-out expected in H2'22
- GBS: 18/30 patients enrolled in the GBS phase 2 study; Significant initiatives were implemented during H1 2022 to support the completion of enrollment in H2 2022

✓ Annual General Meeting held on June 30, 2021

- All resolutions were approved by shareholders
- Peter Nicklin appointed as new Chairman of the Board. Peter Nicklin brings significant experience from leading global teams in large and mid-size life science companies

Events after the reporting period

✓

- First patient was treated in Hansa's European post approval efficacy study (PAES)
- Concluded a USD 70 million non-dilutive financing transaction with NovaQuest Capital Management to support the continued development of Hansa's antibody-cleaving enzyme technology platform across multiple therapeutic areas while extending the expected cash runway through 2024.

Recommendation by NICE is an important step forward for our commercialization efforts and for patients in England, Wales & Northern Ireland

NICE considers Idefirix® to be a clinically- and cost-effective treatment; Market access has now been secured in 7 European countries and procedures are ongoing in 11 countries, including Spain and Italy



[1]Annual kidney transplantations 2019 (pre-Corona)
*Transplantation data is from Global Observatory on Donation and Transplantation, 2019
**Pricing & reimbursement obtained in France on an early access basis

First patient treated in post-authorization efficacy study (PAES) of Idefirix® (imlifidase) in highly sensitized kidney transplant patients

The study will provide further important insights regarding Idefirix® desensitization treatment of highly sensitized kidney transplant patients

An open-label Phase 3 study in 50 patients

- First patient was treated by Dr. Oriol Bestard, Chair of Nephrology and Kidney Transplantation at Vall d'Hebron University Hospital in Barcelona
- Study will enroll 50 highly sensitized patients with positive crossmatch against an available deceased donor across multiple countries and centers in Europe
- The study is an obligation under the conditional marketing authorization for Idefirix® granted by EMA in August 2020, in order to complete a full marketing authorization in the EU
- The aim will be to confirm the long-term efficacy and safety of Idefirix® with the primary objective to determine the one-year graft failure-free survival of the Idefirix® treated and transplanted patients.
- In addition, a total of 50-100 patients undergoing compatible kidney transplantation at the participating centers will be included and serve as a non-comparative concurrent reference cohort, with no formal comparison, to contextualize the one-year graft failure-free survival of the Idefirix® treated patients

Continuous progress in our ongoing clinical Programs

Enrollment status
July 19, 2022

Antibody Mediated Rejection Phase 2 study

- 30/30 patients enrolled in the AMR phase 2 study
- Completion of enrollment expected H1 2022*
- First data read out expected in H2 2022*

- Patients enrolled
- Patients remaining

Guillain-Barré Syndrome Phase 2 study

- 18/30 patients enrolled in the GBS program
- Ten centers are active and open for recruitment
- Significant initiatives were implemented during H1 2022 to support the completion of enrollment in H2 2022*
- First data read out expected in H1 2023

Enrollment status
July 19, 2022

- Patients enrolled
- Patients remaining

Anti-GBM Phase 3 study

- FDA has accepted Hansa's Investigational New Drug (IND) application to proceed with a Phase 3 study
- The planned study will commence this year targeting 50 patients across the U.S. and Europe*

- Patients enrolled
- Patients remaining

U.S. ConfIdeS Phase 3 study

Randomized, controlled trial in highly sensitized kidney transplant patients across up to 15 centers

- 22/64 patients enrolled for randomization
- Ten centers are active and open for recruitment
- Completion of enrollment expected H2 2022*

Guidance assumes no further escalation of the COVID-19 pandemic potentially forcing trial centers to reprioritize patient recruitment or even shut down again.

HANSA BIOPHARMA

Broad clinical pipeline in transplantation and auto-immune diseases

Candidate/ Program	Indication	Research/ Preclinical	Phase 1	Phase 2	Phase 3	Marketing Authorization	Marketed	Next Anticipated Milestone
Imlifidase	EU: Kidney transplantation in highly sensitized patients [1,2]							EU: Additional agreements around reimbursement from H2'21
	US: Kidney transplantation in highly sensitized patients [1,2]							Completion of enrollment (64 patients) H2'22
	Anti-GBM antibody disease [3]							Pivotal Phase 3 study expected to commence in 2022 (50 patients)
	Antibody mediated kidney transplant rejection (AMR)							First data readout H2'22
	Guillain-Barré syndrome (GBS)							Completion of enrollment (30 patients) H2 2022
	Pre-treatment ahead of gene therapy in Limb-Girdle (Partnered with Sarepta)							Preclinical phase
	Pre-treatment ahead of gene therapy in Duchenne (Partnered with Sarepta)							Preclinical phase
	Pre-treatment ahead of gene therapy in Pompe disease (Partnered with AskBio)							Preclinical phase
NiceR	Recurring treatment in autoimmune disease, transplantation and oncology							Completion of GLP toxicology studies in 2022
EnzE	Cancer immunotherapy							Research phase

[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
[3] Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund

Completed
Ongoing
Planned
Post approval study running in parallel with commercial launch

HANSA BIOPHARMA

Continued solid sales in Q2 with product sales of SEK 19.5m; Total H1-2022 revenue SEK 56.7m







Continued investments in commercialization and our pipeline

SG&A expenses (Q/Q)



R&D expenses (Q/Q)



Net loss (Q/Q)



SG&A expenses (HY/HY)



R&D expenses (HY/HY)



Net loss (HY/HY)



With recent financing transaction secured with NovaQuest; Hansa's cash runway has extended through 2024

Operating cash flow (Q/Q)



Cash & short-term investments (Q/Q)



Cash position post recent financing transaction



Operating cash flow (HY/HY)



Number of employees (Q/Q)



$70 million non-dilutive financing transaction to support the continued development of Hansa's antibody-cleaving enzyme technology platform

Transaction extends cash runway through 2024 and helps bolster the ability to invest in the continued development of our unique antibody-cleaving enzyme technology platform across multiple therapeutic areas

Proceeds from the transaction will chiefly be utilized to:

- Further strengthen Hansa's position in kidney transplantation through the continued support of ongoing European commercial launch activities for Idefirix (imlifidase) and execution for the U.S.
- Further fund ConfIdeS trial of imlifidase, which is expected to support a potential Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) under the accelerated approval pathway in the first half of 2024.
- Advance the global Phase 3 clinical trial of imlifidase in anti-GBM antibody disease, and
- Together with the existing cash, complete our ongoing Phase 2 programs in AMR and GBS and to advance Hansa's next generation of enzymes (NiceR) into clinical development



Upcoming milestones

Milestones subject to potential COVID-19 impact



Guidance assumes no persistent impact or further escalation of the COVID-19 pandemic potentially forcing trial centers to reprioritize patient recruitment or even shut down again.

HANSA BIOPHARMA

Q&A

… at Hansa Biopharma we envision a world where all patients with rare immunologic diseases can lead long and healthy lives…

Visit our web site
www.hansabiopharma.com



Corporate Contacts

Investor Relations and
Corporate Communications

Visit our web site
www.hansabiopharma.com

Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com

Katja Margell

Head of Corporate Communications

Mobile: +46 (0) 768-198 326

Email: katja.margell@hansabiopharma.com

Calendar and events

Aug 9, 2022	BTIG Biotechnology Conference 2022, New York
Aug 10, 2022	Kempen US non-deal road show, New York
Aug 11, 2022	Canaccord Annual Growth Conference, Boston
Aug 18, 2022	Penserpodden "Focus on autoimmunity" (virtual)
Aug 24, 2022	Handelsbanken Life Science Innovation Day, Stockholm (virtual)
Aug 31, 2022	Redeye Late-stage Life Science conference, Stockholm
Sept 7, 2022	Pareto annual Healthcare Conference 2022, Stockholm
Sept 8, 2022	Citi's 17th Annual BioPharma Conference, Boston
Sept 12, 2022	H.C. Wainwright Global Investment Conference, New York
Sept 13-14, 2022	MorganStanley Global Healthcare Conference, New York
Sept 20, 2022	Redeye Afterwork presentation, Gothenburg
Sept 21, 2022	Redeye Lunch presentation, Stockholm
Sept 26, 2022	Aktiespararna Aktiedagen, Lund
Oct 20, 2022	**Interim Report for January-September 2022**
Nov 23, 2022	SEB Healthcare Seminar 2022, Stockholm
Nov 24, 2022	Redeye Life Science Day, Stockholm
Dec 1, 2022	Erik Penser Banks Temadag - Health Care, Stockholm


HANSA
BIOPHARMA